These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 28376187)
1. A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity. Ubink I; Elias SG; Moelans CB; Laclé MM; van Grevenstein WMU; van Diest PJ; Borel Rinkes IHM; Kranenburg O J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376187 [TBL] [Abstract][Full Text] [Related]
2. Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT). Ubink I; Bloemendal HJ; Elias SG; Brink MA; Schwartz MP; Holierhoek YCW; Verheijen PM; Boerman AW; Mathijssen RHJ; de Leng WWJ; de Weger RA; van Grevenstein WMU; Koopman M; Lolkema MP; Kranenburg O; Borel Rinkes IHM BMC Cancer; 2017 Apr; 17(1):282. PubMed ID: 28424071 [TBL] [Abstract][Full Text] [Related]
3. Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study. Peters NA; Constantinides A; Ubink I; van Kuik J; Bloemendal HJ; van Dodewaard JM; Brink MA; Schwartz TP; Lolkema MPJK; Lacle MM; Moons LM; Geesing J; van Grevenstein WMU; Roodhart JML; Koopman M; Elias SG; Borel Rinkes IHM; Kranenburg O Front Oncol; 2022; 12():969855. PubMed ID: 36147916 [TBL] [Abstract][Full Text] [Related]
4. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Tamborini E; Miselli F; Negri T; Lagonigro MS; Staurengo S; Dagrada GP; Stacchiotti S; Pastore E; Gronchi A; Perrone F; Carbone A; Pierotti MA; Casali PG; Pilotti S Clin Cancer Res; 2006 Dec; 12(23):6920-8. PubMed ID: 17145809 [TBL] [Abstract][Full Text] [Related]
5. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas. Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867 [TBL] [Abstract][Full Text] [Related]
6. Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine. Mouillet-Richard S; Cazelles A; Sroussi M; Gallois C; Taieb J; Laurent-Puig P Clin Cancer Res; 2024 Jun; 30(11):2351-2358. PubMed ID: 38564259 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964 [TBL] [Abstract][Full Text] [Related]
8. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis. Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155 [TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388 [TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440 [TBL] [Abstract][Full Text] [Related]
11. mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer. Erben P; Horisberger K; Muessle B; Müller MC; Treschl A; Ernst T; Kähler G; Ströbel P; Wenz F; Kienle P; Post S; Hochhaus A; Willeke F; Hofheinz RD Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1544-50. PubMed ID: 19028276 [TBL] [Abstract][Full Text] [Related]
12. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568 [TBL] [Abstract][Full Text] [Related]
13. Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR. Schirosi L; Lantuejoul S; Cavazza A; Murer B; Yves Brichon P; Migaldi M; Sartori G; Sgambato A; Rossi G Am J Surg Pathol; 2008 Nov; 32(11):1627-42. PubMed ID: 18753943 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Ahmed FE; Ahmed NC; Vos PW; Bonnerup C; Atkins JN; Casey M; Nuovo GJ; Naziri W; Wiley JE; Mota H; Allison RR Cancer Genomics Proteomics; 2013; 10(3):93-113. PubMed ID: 23741026 [TBL] [Abstract][Full Text] [Related]